论文部分内容阅读
目的观察吉非替尼治疗晚期非小细胞肺癌(NSCLC)临床疗效与外周T淋巴细胞亚群变化的关系。方法对组织或细胞病理证实的35例晚期NSCLC患者口服吉非替尼250 mg/d。采集全部患者治疗前及治疗后外周血标本,三色染色后流式细胞仪分析CD3+、CD4+、CD8+T淋巴细胞亚群变化。结果35例患者中部分缓解13例,稳定13例,进展9例,疾病控制率为74.2%。治疗前后T淋巴细胞亚群无显著差异。结论吉非替尼治疗晚期非小细胞肺癌疗效较好,毒副反应轻微。治疗后T淋巴细胞可以恢复到治疗前水平。
Objective To observe the relationship between the clinical efficacy of gefitinib in the treatment of advanced non-small cell lung cancer (NSCLC) and the changes of peripheral T lymphocyte subsets. Methods 35 patients with advanced NSCLC confirmed by histology or cytopathology were given gefitinib 250 mg once daily. Peripheral blood samples of all patients before and after treatment were collected, and the changes of CD3 +, CD4 +, CD8 + T lymphocyte subsets were analyzed by flow cytometry after trichrome staining. Results Of the 35 patients, 13 were partially relieved, 13 were stable, 9 were progressive, and the disease control rate was 74.2%. Before and after treatment T lymphocyte subsets no significant difference. Conclusion Gefitinib treatment of advanced non-small cell lung cancer better efficacy, mild side effects. After treatment T lymphocytes can be restored to pre-treatment levels.